2016-08-18
Ark Biosciences Initiates VICTOR Study
Ark Biosciences Inc. announced today that dosing with AK0529, its leading antiviral drug against respiratory syncytial virus (RSV), has commenced in infants hospitalized with RSV infection in the VICTOR (Viral Inhibition in Children...
know more >
2015-09-23
Ark's Anti-RSV AK0529 Successfully Completes Phase 1 Study
SHANGHAI, CHINA- Ark Biosciences, a biotech company developing proprietary therapeutics for respiratory viral diseases and viral hepatitis, today announced the successful completion of phase 1 clinical study of its anti-respi...
know more >
2015-08-04
Ark Completes Series A Financing and Reports Significant Progress for AK0529
SHANGHAI, CHINA- Ark Biosciences, a biotech company developing proprietary therapeutics for respiratory viral diseases and viral hepatitis, announced today successful completion of a Series A financing, led by Qiming Venture ...
know more >
2014-06-16
Ark Biosciences Licenses Novel Drug Candidate from Roche for Potential Treatment of RSV infection
SHANGHAI, CHINA- Ark Biosciences, a biotech startup company focusing on innovative drug discovery and development, today announced a licensing agreement for Roche's Respiratory Syncytial Virus (RSV) drug candidate AK0529. Th...
know more >